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To assess the functional significance of tethering ac-
tin to myosin by caldesmon in the regulation of smooth
muscle contraction, we investigated the effects of syn-
thetic peptides, containing the myosin-binding se-
quences in the N-terminal region of caldesmon, on force
directly recorded from single permeabilized smooth
muscle cells of ferret portal vein. Two peptides were
used, IK29C and MY27C, containing residues from Ile25
to Lys53 and from Met1 to Tyr27 of the human and
chicken caldesmon sequence, respectively, plus an
added cysteine at the C terminus. In cells clamped at
pCa 6.7, both peptides increased basal tone. Pretreat-
ment of cells at pCa 6.7 with IK29C or MY27C decreased
the amplitude of subsequent phenylephrine-induced
contractions but not microcystin-racemic mixture-in-
duced contractions. In all cases the effects of the pep-
tides were concentration-dependent, and IK29C was
more potent than MY27C, in agreement with their rela-
tive affinity toward myosin. The peptides were ineffec-
tive after the phenylephrine contraction was estab-
lished. MY27C did not further increase the magnitude of
contraction caused by a maximally effective concentra-
tion of IK29C, consistent with the two peptides having
the same mechanism of action. Neither polylysine nor
two control peptides containing scrambled sequences of
IK29C, which do not bind myosin, had any effect on
basal or phenylephrine-induced force. Our results sug-
gest that IK29C and MY27C induce contraction by com-
peting with the myosin-binding domain of endogenous
caldesmon. Digital imaging of fluoroisothiocyanate-
tagged IK29C confirmed the association of the peptide
with intracellular filamentous structures. The results
are consistent with a model whereby tethering of actin
to myosin by caldesmon may play a role in regulating
vascular tone by positioning the C-terminal domain of
caldesmon so that it is capable of blocking the actomy-
osin interaction.
Phosphorylation of Ser19 of the 20-kDa myosin light chain
(LC20)
1 by Ca21-calmodulin-dependent myosin light chain ki-
nase (MLCK) has clearly been shown to represent a major
pathway for the regulation of contractile force in vascular
smooth muscle (1–2). However, regulation by LC20 phosphoryl-
ation may not explain all aspects of smooth muscle contractil-
ity. In particular, with respect to tonic contractile responses,
many examples of dissociation between force levels, LC20 phos-
phorylation levels, intracellular Ca21 concentration ([Ca21]i),
and cross-bridge cycling rates have been reported (2–5), and
the possible existence of a secondary regulatory mechanism for
smooth muscle contraction is difficult to negate. Although the
precise mechanism involved in this additional regulatory sys-
tem has not yet been identified, one likely candidate for medi-
ating this regulation is the thin filament-associated protein
caldesmon.
Smooth muscle caldesmon consists of three parts (Fig. 1),
N-terminal, C-terminal, and an elongated central spacer region
(6–7). The C-terminal portion of the molecule contains binding
sites for actin and tropomyosin and inhibits actin-activated
ATPase activity of myosin in vitro (8–15). Both N- and C-
terminal fragments include binding sites for calmodulin (16–
17). The N-terminal portion of the molecule also contains a
binding site for myosin that may be involved in tethering actin
to myosin (18).
Evidence that caldesmon is involved in the regulation of
contraction has been reported from several groups using differ-
ent approaches. We have previously reported the effect of a
peptide, GS17C, that contains residues from Gly651 to Ser667 of
the C-terminal caldesmon sequence. The peptide binds actin
but does not inhibit actomyosin ATPase activity and when used
in saponin-permeabilized single ferret aortic and portal vein
cells produced a sustained contraction (19). It was postulated
that the contraction was due to competition with and partial
displacement of endogenous caldesmon, resulting in disinhibi-
tion of myosin ATPase activity (19). It has been reported that
extraction of caldesmon from a permeabilized smooth muscle
preparation increased the Ca21 sensitivity of force develop-
ment (20) and, conversely, that addition of caldesmon or a
C-terminal fragment to permeabilized chicken gizzard fibers
inhibited contraction (21–22). It has also been reported re-
cently that, in arterial strips made caldesmon-deficient by the
use of antisense oligodeoxynucleotides, increased basal cross-
bridge cycling rates are inhibited by the addition of caldesmon
(23).
Most investigations into the possible role of caldesmon in
smooth muscle contractility have focused on the role of the
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C-terminal part of caldesmon. However, because caldesmon
contains both actin (C-terminal) and myosin (N-terminal) bind-
ing domains, both have been postulated to play a role in force
maintenance in smooth muscle through a tethering effect that
may maintain contractile force in the absence of cross-bridge
cycling (24). As an alternative hypothesis, tethering has also
been postulated to function as in a structural manner, keeping
the contractile filaments in register (25). However, at the pres-
ent time, direct evidence is still lacking for a role of the N-
terminal part of caldesmon in the contraction of smooth muscle
cells.
Thus, we synthesized a 29-residue peptide, IK29C,2 and a
27-residue peptide, MY27C (26–27), which contain residues
from Ile25 to Lys53 and from Met1 to Tyr27, derived from the
myosin-binding domain of human and chicken caldesmon se-
quence, respectively, with an added cysteine at the C terminus.
Both peptides have been shown to bind to smooth muscle my-
osin, but IK29C binds more strongly than does MY27C.2 To test
the hypothesis that tethering of caldesmon may function as a
physiological regulator of vascular tone, we determined the
effects of IK29C, MY27C, and related peptides on contractility
in a single hyperpermeable cell system (28–29). Our results
strongly suggest that IK29C and MY27C induce contraction by
competing with the myosin-binding domain of endogenous
caldesmon and, furthermore, that tethering of caldesmon may
play a role in regulating vascular tone by properly positioning
the C terminus of caldesmon so that it can maximally inhibit
the actin-activated myosin ATPase.
EXPERIMENTAL PROCEDURES
Peptides and Drugs—All peptides were synthesized as amides on an
automated peptide synthesizer (ABI-431A) on a 0.25-mmol scale using
the “FastMoc” method (30), a procedure similar to the Fmoc protocol
except the activation is performed with 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate, instead of by carbodiimide-
mediated reactions. 1.2 g of Rink (4-(29,49-dimethoxyphenyl-Fmoc-ami-
nomethyl)-phenoxy) resin (Advanced ChemTech, Louisville, KY)) was
used for each synthesis. After synthesis the peptides were cleaved from
the resin according to a trifluoroacetic acid-based protocol in a solution
containing 0.75 g of phenol, 0.25 ml of 1,2-ethanedithiol, 0.5 ml of
thioanisole, 10.0 ml of trifluoroacetic acid, and 1.0 ml of H2O at room
temperature. To ensure complete removal of the protecting group
(2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride) for Arg residues,
the reaction time was increased to 4 h for IK29C and its variants. After
cleavage/deprotection reaction the peptide was precipitated upon drop-
wise addition of the reaction mixture into cold diethyl ether. The pep-
tide was then spun down, washed by ether, dialyzed against water, and
lyophilized.
The peptides were first examined by reversed phase high pressure
liquid chromatography using an analytical C-8 column (Si-O-Si-(CH2)7-
CH3 from Phenomenex, Torrance, CA; length, 250 mm; internal diam-
eter, 4.6 mm; particle size, 5 mm). About 100 ml of 2 mg/ml of peptide
solution (in water) was injected each time, and the column was eluted
with a 0–60% acetonitrile gradient containing 0.1% trifluoroacetic acid
at a flow rate of 1 ml/min. The peptides were eluted with increasing
concentrations of Solution B (100% acetonitrile plus 0.1% trifluoroacetic
acid). The peptides were then purified using a semi-preparative C-8
column (length, 250 mm; internal diameter, 10 mm; particle size, 5 mm)
with an injection volume of 500 ml (of 2 mg/ml) and a flow rate of 2
ml/min. The bulk of each peak was collected, dialyzed against water,
and lyophilized. All peptides thus purified were confirmed by both
amino acid composition and partial sequence analyses and were further
checked by MALDI-TOF mass spectrometry (Perspective Biosystems,
Voyager RP) to ascertain the purity and complete removal of protecting
groups. In each case a single major peak was obtained; their respective
masses (m/z) were 3817.72 (IK29C), 3815.96 (IK29CX1), 3814.79
(IK29CX2), and 3765.95 (MY27C).
The following drugs were used: PE, creatine kinase, phosphocreat-
ine, and microcystin-LR (all from Sigma). General laboratory reagents
were of analytical grade or better and were purchased from Sigma or
Fisher.
Solutions—Ca21 buffers were prepared according to an iterative
computer program that calculates the amounts of stock solutions re-
quired for a given set of free ion concentrations, taking into consider-
ation the binding constants for the ionic species present, temperature,
and ionic strength (28). Ionic strength was set at 0.2 M, and MOPS was
used to buffer the pH at 7.0. The concentrations of the constituents were
as follows: Ca21, 1 nM TO 0.1 mM; Mg21, 1 mM; K1, 135 mM; MgATP, 3
mM; EGTA, 15 mM; MOPS, .15 mM; phosphocreatine, 15 mM; and
creatine kinase (approximately 20 units/ml), added daily before the
experiments. The major anion was propionate. Krebs solution (used
only for dissection of the tissue) contained (in mM) 120 NaCl, 5.9 KCl,
2.5 CaCl2, 1.2 MgCl2, 25 NaHCO3, 1.2 NaH2PO4, and 11.5 dextrose at
pH 7.4 when bubbled with 95% O2 1 5% CO2. The Ca
21-Mg21-free
Hank’s balanced salt solution (HBSS) used for cell isolation contained
(in mM) 137 NaCl, 5.4 KCl, 0.44 KH2PO4, 4.17 NaHCO3, 0.42 NaH2PO4,
and 5.5 dextrose, 10 HEPES, pH 7.4.
Tissue Preparation and Single Cell Isolation—All procedures were
performed according to protocols approved by the Institutional Animal
Care and Use Committee. Ferrets were euthanized with chloroform,
and the portal vein was quickly removed to a dissection dish filled with
oxygenated Krebs solution. The tissue was cleaned of connective tissue
and opened longitudinally, and the endothelium was removed by gentle
abrasion of the inner surface of the tissue with a rubber policeman. The
tissue was cut into 2–3-mm-wide strips, and wet weight was deter-
mined. Single vascular smooth muscle cells from ferret portal vein were
isolated using a modification of a previously published method (29). The
portal vein was cut into small pieces (2 3 2 mm) and placed in a
siliconized flask containing digestion medium. For each 50 mg of portal
vein (wet weight), the digestion medium A consisted of 4.2 mg of CLS 2
collagenase (type II, 228 units/mg; Worthington) and 4 mg of elastase
(Grade II, 3.65 units/mg; Roche Molecular Biochemicals) in 7.5 ml of
Ca21-Mg21-free HBSS and 1% bovine serum albumin (Life Technolo-
gies, Inc.). The tissue pieces were incubated in a shaking water bath at
34 °C under an atmosphere of 95% O2 1 5% CO2 for 45 min. The pieces
were then filtered on a nylon mesh, rinsed with 10 ml of Ca21-Mg21-free
HBSS, and reincubated for 20 min in digestion medium B, i.e. the same
digestion solution except for a decrease in the amount of collagenase to
2.1 mg and addition of 5,000 units of soybean trypsin inhibitor (type
II-S; Sigma). The tissue pieces were filtered and rinsed in 10 ml of
Ca21-Mg21-free HBSS. The filtrate containing the dissociated cells was
poured over unsiliconized glass coverslips and further incubated for 20
min in digestion medium B. After filtering and rinsing with 10 ml of
Ca21-Mg21-free HBSS, the dissociated cells were plated onto another
set of coverslips. Coverslips were stored on ice for 1–5 h until use. Cells
were not centrifuged or aspirated by pipette. The isolated cells were
assayed daily to confirm that they shortened in response to 1025 M PE
in 2.5 mM Ca21-HBSS.
Permeabilization and Tension Measurement—The coverslips were
placed on the movable stage of a Nikon inverted microscope. Ferret
portal vein cells were exposed to a relaxing solution (pCa 9) containing
30 mg/ml saponin for 5 min, and then the solution was changed to
saponin-free pCa 6.7 solution. Permeabilized cells were chosen accord-
ing to the following criteria: diminished phaseluscence under phase-
contrast optics; a visible nucleus; length $ 100 mm; and firm attach-
ment to the coverslip. We have previously found that our
permeabilization method results in cells that retain receptor-coupled
function (29) and does not cause a detectable loss of molecules such as
calmodulin (28). Microtools (Glass 1, Life Technologies, Inc., W/FIL 1.0
mm, 1B100F-4, 12773–08H, World Precision Instruments, Sarasota,
FL) were prepared by the use of a micropipette puller (Industrial
Science Associates, Inc. Ridgewood, NY), and the diameters of the tip of
the microtool were , 5 mm. The microtools were placed with their tips
touching the top surface of the cell (microtools approached the coverslip
at an angle of approximately 45°), and the cells were left undisturbed
for 2–3 min. We have found that mammalian vascular smooth muscle
cells prepared in this manner have the important advantage of sticking
to glass and, therefore, readily attach to the glass microelectrodes. The
microtool attached to the transducer (Cambridge model 400A) was
lifted so that the end of the cell was raised off the coverslip. The other
microtool was gently pressed down to immobilize the other end of the
cell, which was stretched to approximately 110% of its original length.
Control recordings confirmed the drift of the transducer was negligible
over the course of the recording. At least one recording was made daily
with a cell attached to the microtool in the absence of added drugs to
2 Y. Li, S. Zhuang, K. Mabuchi, R. C. Lu, and C.-L. Albert Wang,
unpublished results. Co-sedimentation experiments showed that both
MY27C and IK29C bind smooth muscle myosin. The scrambled pep-
tides, IK29CX1 and IK29CX2, however, did not appreciably co-sedi-
ment with myosin.
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confirm that the base line drifted #10 mg over the time course of an
experiment. Additionally, base-line recordings of 3–5 min were ob-
tained for each cell before experimental manipulations were performed.
Agonist-induced increases or decreases in force were assumed to have
reached a plateau when no further increase or decrease occurred over a
2–3-min period. Force records were quantitated by placing a ruler on
the trace through the midpoint of the noise level. All experiments were
performed at 20–21 °C.
Digital Imaging—Isolated portal vein cells were incubated in pCa 6.7
solution containing FITC-labeled IK29C peptide (5 mM) and saponin (30
mg/ml) for 10 min. The cells were then rinsed with pCa 6.7 solution
several times, fixed with 4% paraformaldehyde, and mounted with
Fluorosave (Calbiochem) before analysis. Images were obtained using a
Nikon Diaphot 300 inverted microscope equipped with a Nikon X-40 oil
immersion objective (NA 1.3). Filters used were 470 6 20 nm (excita-
tion), 505 nm (dichroic), and 535 6 20 nm (emission) for FITC-labeled
cells. Images were recorded with a liquid cooled charge-coupled device
(CCD) camera (photometrics CH250) via Photometrics Microsoft-com-
patible Image-processing Software (PMISTM).
For the comparison of LC20 phosphorylation levels, cells were co-
stained with a monoclonal (mouse) antibody (1:500) specific for phos-
phorylation of LC20 at the MLCK sites, which was a gift from Drs. Y.
Sasaki and M. Seto (Asahi Chemical Industry Co., Fuji, Japan) and has
been previously characterized (31) and with rhodamine phalloidin (1:
2000, Molecular Probes) to label actin. For data analysis, a region was
identified containing a filament bundle, and fluorescence for both LC20
phosphorylation and actin were quantitated and integrated, and the
ratio of LC20 phosphorylation fluorescence/actin fluorescence was cal-
culated. Normalization of phosphorylation values by the actin content
compensated for any differences in cell thickness, etc., between cells.
The anti-phospho-LC20 signal was visualized with an Oregon Green-
labeled goat anti-mouse secondary antibody (1:500, Molecular Probes).
The Oregon Green signal was excited at 485 6 5.2 nm, and emission
was measured through a dichroic filter at .500 nm and an emission
filter at 515 6 4 nm. The rhodamine signal was excited at 546 6 12 nm,
and emission was measured through a dichroic filter at .580 nm and a
barrier filter at .590 nm. Cells labeled only with Oregon Green were
viewed with the rhodamine filter set, and cells labeled only with rho-
damine were viewed with the Oregon Green filter set to confirm that
there was no significant cross-talk between channels at the gain set-
tings used.
Myosin and Actomyosin ATPase Activity Assays—Both unphospho-
rylated and phosphorylated recombinant gizzard HMM (expressed in
insect cells from a clone kindly given by Dr. M. Ikebe) were used. For
myosin phosphorylation, to purified HMM (0.97 mg/ml) in 50 mM NaCl,
20 mM Tris, pH 7.5, 1 mM dithiothreitol were added: 50 ml of recombi-
nant rabbit smooth muscle MLCK (6.36 mM; a gift from Dr. Z. Graba-
rek), 1.2 ml of calmodulin (267 mM), 5.25 ml of ATP (0.2 M, pH 7.4), 0.2 ml
of CaCl2 (1 M), 1.05 ml of MgCl2 (1 M), at room temperature; total volume
1 ml; the mixture was incubated for 2 h and stored on ice. Immediately
before the ATPase assay, phosphorylated HMM was passed through a
gel filtration column at room temperature to remove ATP. ATPase was
assayed by a continuous spectrophotometric method using 2-amino-6-
mercapto-7-methylpurine ribonucleoside/purine nucleoside phosphoryl-
ase reaction to detect the released inorganic phosphate (EnzChek Kit
from Molecular Probes, Eugene, OR) (32). Reaction conditions are as
follows: 30 mM NaCl, 10 mM HEPES, pH 7.5, 5 mM MgCl2, 0.2 mM
CaCl2, 0.5 mM ATP, 25 °C; 10–30 mg/ml phosphorylated or unphospho-
rylated HMM, 4 mM actin, 0.57 mM tropomyosin; total volume 5 0.5 ml.
Statistics—All values given in the text are mean 6 S.E. Differences
between mean were evaluated using Student’s t test. Significant differ-
FIG. 1. Domain structure of caldesmon. The numbering of the complete caldesmon sequence corresponds to that of chicken gizzard isoform.
The positions of IK29C (from Ile25 to Lys53 from the human sequence) and MY27C (Met1 to Tyr27 from the chicken sequence) are also shown.
FIG. 2. Effects of IK29C or MY27C
on basal tension. In all panels, tension
was recorded from single permeabilized
portal vein cells at pCa 6.7. A, concentra-
tion dependence of IK29C-induced in-
creases in basal tension. B, concentration
dependence of MY27C-induced increases
in basal tension. C, control trace. Dotted
line indicates basal force at pCa 6.7. Con-
centrations (mM) of IK29C and MY27C,
respectively, are shown. D, statistical
analysis of the effects of IK29C and
MY27C on basal tension; *, p , 0.05 com-
pared with contraction induced by
MY27C.
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ences were taken at the p , 0.05 level. The values given represent
numbers of cells used in each experiment.
RESULTS
N-terminal Caldesmon Peptides Increase Resting Tension—
Peptide IK29C contains 29 amino acid residues, IAYQRND-
DDEEEAARERRRRARQERLRQK, which correspond to the
human caldesmon sequence from Ile25 to Lys53 (Fig. 1), plus a
cysteine residue added at the C terminus. Peptide MY27C
contains 27 amino acid residues, MDDFERRRELRRQKREEM-
RLEAERLSY, which corresponds to the chicken caldesmon
sequence from Met1 to Tyr27 (Fig. 1), and a C-terminal cysteine
residue. The effects of these peptides on resting tension of
single permeabilized ferret portal vein cells are illustrated in
Fig. 2. In cells in which Ca21 was clamped at pCa 6.7, both
peptides induced a gradual but sustained increase in contract-
ile force (Fig. 2, A and B). The mean steady-state increase in
force in response to IK29C was 74 6 7.5 mg (n 5 5) at 1 mM,
142 6 6.1 mg (n 5 6) at 2.5 mM, 254 6 17.1 mg (n 5 6) at 5 mM,
258 6 11.4 mg (n 5 5) at 10 mM, and 257 6 10.6 mg (n 5 5) at
20 mM. In the case of MY27C, the mean steady-state amplitude
of contraction was 22 6 9.7 mg (n 5 5) at 1 mM, 83 6 12 mg (n 5
6) at 2.5 mM, 134 6 14 mg (n 5 5) at 5 mM, 200 6 10.9 mg (n 5
5) at 10 mM, and 206 6 14.5 mg (n 5 3) at 20 mM. In both cases,
the peptide-induced contractions were concentration-depend-
ent, but IK29C was more potent and more effective than
MY27C. The maximal force developed by the peptides was
258 6 11.4 mg for IK29C and 206 6 14.5 mg for MY27C,
respectively. The 50% effective concentrations (EC50) of IK29C
and MY27C were 1.98 and 3.4 mM, respectively.
PE and Microcystin-LR Effects Are Additive—The effects of
PE and microcystin-LR on the contractility of single permeabi-
lized ferret portal vein cells are illustrated in Fig. 3. As shown
in Fig. 3A1, a maximally effective concentration of PE (1025 M)
evoked a gradual but sustained contraction of permeabilized
FIG. 3. Effects of pretreatment with IK29C or MY27C on PE- or microcystin-LR-induced contraction. A1, effects of PE (1025 M) and
subsequent addition of microcystin-LR (1 mM) on single cell contractility. A2–A5, effects of pretreatment of the cells with IK29C on PE- or
microcystin-LR-induced contractions. A6, control recording. Dotted line indicates base-line force at pCa 6.7. B1 and B2, average results of the effects
of pretreatment with IK29C (B1) or MY27C (B2) on PE- and microcystin-LR-induced contraction (n 5 5;7). B3, average effect of 1 mM
microcystin-LR and subsequent addition of 1025 M PE (n 5 5).
FIG. 4. Effects of pretreatment with
scrambled IK29C on PE- or microcys-
tin-LR-induced contractions. A, force
recording in response to PE (PE, 1025 M)
and microcystin-LR (1 mM). B and C, ef-
fects of pretreatment of the cells with
IK29CX1 (B) or IK29CX2 (C) on PE- or
microcystin-LR-induced contraction. D,
control recording. Dotted line indicates
base-line force at pCa 6.7. E, average re-
sults of pretreatment with IK29CX1 (n 5
4) or IK29CX2 (n 5 5) on PE- and micro-
cystin-LR-induced contraction.
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portal vein cells clamped at pCa 6.7. The mean steady-state
increase in force in response to PE was 266 6 20.2 mg (n 5 7)
(Fig. 3B1). When portal vein cells were stimulated by PE, the
subsequent addition of mycrocystin-LR (1 mM) caused a further
increase in force generation above that induced by PE (Fig.
3A1), and the mean steady-state increase was 206 6 27.2 mg
(n 5 7) (Fig. 3B1). We have previously shown that ferret portal
vein and aortic cells contract in response to PE at near resting
[Ca21]i levels in the absence of changes in LC20 phosphoryla-
tion, and this contraction is associated with activation of pro-
tein kinase C and mitogen-activated protein kinase (MAPK)
and phosphorylation of the C-terminal half of caldesmon (29,
33–36). In contrast, it is known that microcystin-LR is an
inhibitor of myosin light chain phosphatase that causes con-
traction by increasing LC20 phosphorylation levels (37). We
have previously shown that microcystin-LR provokes a contrac-
tion in single permeabilized ferret cells independent of activa-
tion of protein kinase C (38). The additivity of the PE and
microcystin-LR responses is consistent with their having dif-
ferent mechanisms of action.
It is of interest that when mycrocystin-LR was added first, it
induced a larger contraction (284 6 12.1 mg, n 5 5, Fig. 3B3,
p 5 0.04) than when microcystin-LR was added after PE con-
traction was established (206 6 27.2 mg, n 5 7, Fig. 3B1).
Similarly, post-treatment of cells with PE after the induction of
a microcystin-LR contraction evoked an average, smaller con-
traction (222 6 12 mg, n 5 5, Fig. 3B3, p 5 0.102) than that
caused by PE alone (266 6 20.2 mg, n 5 7 Fig. 3B1), although
the difference did not reach statistical significance. When the
sum of the PE and microcystin-LR contractions was compared
across the different protocols (Fig. 3B1, 2, and 3), it was noticed
that the total force produced was remarkably similar, between
480 and 500 mg. Thus, it appears that there is a “ceiling” of
about 500 mg on the total force that a single ferret portal vein
cell can generate.
N-terminal Caldesmon Peptides Inhibit PE but Not Micro-
cystin-LR Contractions—The effects of pretreatment of single
permeabilized ferret portal vein cells with IK29C or MY27C on
the PE- or microcystin-LR-induced contraction are illustrated
in Fig. 3. Pretreatment of the cells with IK29C or MY27C
decreased the amplitude of PE-induced contractions but not
that of microcystin-LR-induced contractions. As shown in Fig.
3A, as the concentration of IK29C or MY27C increased, the
effect on basal tension also increased but the amplitude of the
subsequent PE-induced contraction decreased. In contrast, in-
creasing concentrations of the peptides had no effect on the
magnitude of the microcystin-LR-induced contraction. Fig. 3,
B1 and B2, show the sum of the mean peptide-, PE-, and
microcystin-LR-induced contraction in the presence of various
concentrations of the peptide. At 1 mM IK29C, the IK29C-
induced contraction was 74 6 7.5 mg (n 5 5), and the amplitude
of PE- or microcystin-LR-induced contraction was 188 6 13.6
mg (n 5 5) and 212 6 7.4 mg (n 5 5), respectively. However, in
10 mM IK29C, the IK29C-induced contraction was increased to
258 6 11.4 mg (n 5 5), and PE-induced contraction was de-
creased to 23 6 13.9 mg (n 5 5), but microcystin-LR-induced
contraction (212 6 5.8 mg, n 5 5) was not altered. The inhibi-
tion of the PE-induced contraction by the peptides was concen-
tration-dependent, and again, IK29C was more potent than
MY27C.
Two different scrambled versions of IK29C, IK29CX1 (RE-
AERARQREIDLRAREKQ RAERYDQRND-C) and IK29CX2
(EEEEEDDDQQAAALIYQNRRRRRRARRRK-C), were syn-
thesized and were tested for effects on contractility. 5 mM
IK29CX1 or IK29CX2 produced little or no increase in resting
tension (Fig. 4) and had no detectable effect on PE- or micro-
cystin-LR-induced contractions. The amplitude of contraction
in response to PE with or without IK29CX1 was 253 6 17 mg
(n 5 4) and 266 6 20.2 mg (n 5 7), respectively. The amplitude
of contraction in response to microcystin-LR with or without
IK29CX1 was 208 6 12.5 mg (n 5 4) and 206 6 27.2 mg (n 5 7),
FIG. 5. Effect of polylysine on basal and PE-induced contractions. Polylysine was added to single permeabilized cells in pCa 6.7 buffer
either after treatment with PE in A or before PE treatment in B. Polylysine had no effect on basal tone. There was no significant effect of polylysine
on PE-induced contractions in either the pretreatment or post-treatment protocol (C) (n 5 6).
FIG. 6. Effects of pretreatment of cells with IK29C on MY27C-
induced contraction. A, force recording in response to IK29C (5 mM)
and subsequent addition of MY27C (5 mM). B, control recording. Dotted
line indicates base-line force at pCa 6.7. C, average response to pre-
treatment with IK29C, followed by MY27C (n 5 5).
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respectively. 5 mM IK29CX2 had similar results to IK29CX1.
Although IK29CX2 was designed to retain the polyarginine
motif of IK29C, since polylysine has been reported to activate
smooth muscle in a phosphorylation-independent manner (39),
we directly tested the effect of polylysine in our system. How-
ever, even at the maximally effective concentration of IK29C
with respect to contraction, polylysine had no effect on (Fig. 5)
basal or phenylephrine-induced force in either a post-treat-
ment (Fig. 5A) or a pretreatment (Fig. 5B) protocol.
If IK29C and MY27C have the same mechanism of action,
then their maximal effects should not be additive. Indeed, as
shown in Fig. 6, MY27C (5 mM) did not further increase the
magnitude of contraction caused by a maximally effective con-
centration of IK29C (5 mM).
N-terminal Caldesmon Peptides Are Ineffective after PE-in-
duced Contraction Is Established—The effects of IK29C or
MY27C added after the PE-induced response had reached
steady state are illustrated in Fig. 7. As shown in Fig. 7, when
portal vein cells were stimulated by a maximally effective con-
centration of PE (1025 M), the subsequent addition of IK29C
(Fig. 7, B and E) or MY27C (Fig. 7, C and E) had no obvious
effect on PE-induced contractions. As shown in Fig. 7A, the
interpretation of the results was complicated by the fact that,
with time, the PE-induced contraction tended to decrease
slightly. When average results (Fig. 7E, n 5 5) were compared
at the same time points, however, there were no significant
differences with and without the peptides.
FITC-labeled IK29C Distributes Non-homogeneously in
Cells—Since IK29C and MY27C were postulated to alter con-
tractility by competing with caldesmon for its binding site on
myosin,we performed digital imaging experiments using FITC-
IK29C to confirm internalization and verify whether the pep-
tide has an intracellular distribution consistent with associa-
tion with myosin filaments. As shown in Fig. 8, fluorescence
appeared in a non-homogeneous, punctate distribution, run-
ning in a filamentous pattern parallel to the long axis of the
cell. The staining pattern does not prove, but is consistent with,
the distribution of FITC-labeled peptide along the bundles of
contractile filaments in this cell type (40). The fact that the
peptide was internalized in the core of the cell was confirmed
by optical sectioning of the cell images.
IK29C Does Not Alter LC20 Phosphorylation in Cells—It is
possible that the increase in force caused by IK29C could be
due to an unknown effect of the peptide to increase phospho-
rylation of LC20. For this reason, we assessed relative LC20
phosphorylation levels using an antibody specific for LC20
phosphorylated at the MLCK sites, as described under “Exper-
imental Procedures.” Co-staining of actin with rhodamine phal-
loidin was used for normalization. As can be seen in Fig. 9, A
and B, both stains characteristically labeled structures in sim-
ilar filamentous bundles. The actin signal is expected to be
constant except for changes in cell thickness at different pCa
values. When the ratio of the phospho-LC20 signal to the actin
signal was calculated (Fig. 9C), it was found to increase mark-
edly between pCa 6.7 and 5.0 but not between pCa 6.7 and 6.7
plus peptide.
IK29C Does Not Directly Alter Actomyosin ATPase Activity—
Another possibility is that the increase in force caused by
IK29C is due to a direct effect to increase myosin ATPase
activity in the absence of light chain phosphorylation. Thus, we
determined the effect of 10 mM IK29C on myosin ATPase activ-
ity and on actin-activated myosin ATPase activity as described
under “Experimental Procedures.” As is shown in Table I,
although the addition of actin to unphosphorylated HMM
caused a small increase in ATPase activity and the addition of
actin to phosphorylated HMM caused a marked increase in
ATPase activity, the addition of IK29C to unphosphorylated
actomyosin caused no increase in ATPase activity.
DISCUSSION
The main purpose of the present study was to investigate a
possible physiological role for N-terminal domain of caldesmon
in the regulation of smooth muscle tone by using synthetic
peptides based on N-terminal caldesmon sequences as experi-
mental tools. It has been reported that caldesmon binds to
smooth muscle myosin subfragment 2 (41) and that the binding
site resides in the N-terminal region of caldesmon (25, 42). It
has been reported that the major myosin-binding site is present
between residues 24 and 53 of chicken gizzard smooth muscle
caldesmon and that a second, weaker site may be present
between residues 1 and 23 (25). It has also been reported by
another group that two functionally different myosin-binding
sites are located in residues 1–28 and 29–128 of chicken giz-
zard caldesmon (42). IK29C, a synthetic peptide corresponding
to the human caldesmon sequence from Ile25 to Lys53, is found
to bind strongly to smooth muscle myosin.2 MY27C binds less
strongly2 and was less potent and less effective in the present
study, consistent with the myosin binding domain of caldesmon
being primarily located between residues 25 and 53, but also, to
a lesser extent, extending to the N terminus.
FIG. 8. Localization of IK29C. Resting portal vein cell showing
localization of FITC-labeled IK29C. Cell diameter at widest point is ;7
mm. See text for details.
FIG. 7. Effects of post-treatment
with IK29C or MY27C on PE-induced
contraction. A, force recording in the
presence of PE (1025 M). B, effects of in-
creasing concentration (mM) of IK29C (ar-
rows) on PE-induced contraction. C, ef-
fects of increasing concentration (mM) of
MY27C (arrows) on PE-induced contrac-
tion. D, control recording. Dotted line in-
dicates base-line force at pCa 6.7. Solid
line above PE, IK29C, or MY27C, expo-
sure period to PE or peptide. E, average
results on the effects of IK29C or MY27C
on the PE-induced contraction (n 5 5).
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In the present study, we have introduced these peptides into
single permeabilized portal vein cells to test the hypothesis
that the binding of N-terminal caldesmon to myosin is impor-
tant for the regulation of smooth muscle tone, either in the
maintenance of force in the absence of cross-bridge cycling or as
a structural protein, keeping the contractile proteins in proper
register. We postulated that IK29C would displace endogenous
caldesmon from myosin by binding the same site on myosin.
Consistent with this hypothesis digital imaging studies con-
firmed that FITC-labeled IK29C introduced into cell binds
discretely to structures that are organized in a filamentous
pattern running down the long axis of the cell. We also found
that IK29C, but not two scrambled peptides that do not bind
myosin, induced a concentration-dependent increase in resting
tone. These findings strongly suggest that the interference
with N-terminal binding of caldesmon to myosin has a signifi-
cant physiologic effect on vascular tone.
One of the control peptides used, IK29CX2, was designed to
retain the polyarginine motif of IK29C, but because polylysine
hasbeenreportedtocontractsmoothmuscleinaphosphorylation-
dependent manner, we also tested the effect of polylysine.
However, none of these peptides had any detectable effect on
force.
Since phosphorylation of LC20 results in an increase in actin-
activated myosin ATPase activity and an increased contractil-
ity, it was possible that IK29C might have nonspecific effects to
either increase LC20 phosphorylation or to increase directly
myosin ATPase activity. Thus, we compared phospho-LC20 lev-
els in individual cells with or without the peptide and in vitro
myosin ATPase activity in the presence and absence of the
peptide. We were unable to see any detectable effect of the
peptide on phosphorylation or ATPase activity, consistent with
an effect of the peptide specifically on interaction between the
N-terminal segment of caldesmon and myosin.
FIG. 9. Measurement of relative LC20 phosphorylation levels. Cells were co-labeled with an antibody specific for LC20 phosphorylated at
the MLCK sites (A) and rhodamine phalloidin to label actin (B). For data analysis, a region containing a filament bundle was identified, and both
LC20 phosphorylation-induced fluorescence and actin-induced fluorescence were quantitated and integrated for the same region. The ratios of LC20
phosphorylation to actin signals were compared in 9–13 cells in the presence of pCa 5, pCa 6.7 alone, or pCa 6.7 plus 10 mM IK29C (C).
FIG. 10. Schematic representation of the possible mechanism
of peptide- or PE-induced contraction. Phosphorylation is indi-
cated by P. Italics indicated the activated (phosphorylated), in C-CaD or
detached state from myosin molecule, in N-CaD. N-CaD, N-terminal of
caldesmon; C-CaD, C-terminal of caldesmon. See text for details.
TABLE I
Assay of in vitro myosin ATPase activity
Proteins Rate
mmol Pi/mg HMM z min
pHMM 1 actin 0.171
pHMM alone 0.034
HMM alone #0.02
HMM 1 IK29C (10 mM) 0.022
HMM 1 actin 0.046
HMM 1 actin 1 IK29C (10 mM) 0.037
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Another major finding of the present study was that pre-
treatment of the cells with IK29C inhibited PE-induced con-
tractions but not microcystin-LR-induced contractions. It has
previously been reported that the a-adrenergic agonist, PE,
elicits a contraction in ferret vascular smooth muscle cells, and
this contraction is associated with phosphorylation of the C-
terminal domain of caldesmon by activation of protein kinase C
and MAPK (2, 35–36, 43). Conversely, microcystin-LR is known
to be an inhibitor of myosin light chain phosphatase and to
contract smooth muscle in the absence of changes in [Ca21]i by
increasing LC20 phosphorylation (37). Thus, in this system, at
low [Ca21]i levels, PE is expected to cause contraction through
thin filament regulation, whereas microcystin-LR is expected
to cause contraction through thick filament regulation. In the
present study, we found that PE and microcystin-LR responses
are additive, consistent with their having different and inde-
pendent mechanisms of action. The fact that the PE contraction
but not the microcystin-LR contraction was affected by the
(N-terminal) caldesmon peptides points to a specific disruption
of thin filament regulation.
The fact that the increased contractile force caused by N-
terminal caldesmon peptides and PE are not additive suggests
a common, thin filament-based mechanism of action. However,
as described above, the PE-induced contraction at constant
[Ca21]i is thought to result in alleviation of the inhibitory effect
of C-terminal caldesmon on actin-activated myosin ATPase
activity, possibly by phosphorylation of the C-terminal of
caldesmon by MAPK (35–36) (Fig. 10B). IK29C is derived from
the N-terminal domain of caldesmon, which binds myosin, and,
thus, one might expect addition of the peptide to break tethers
and cause global relaxation of all contractions. This is not what
was seen. Rather, a selective prevention of PE contractions but
not microcystin contractions was seen. However, the results of
the present study are consistent with a modified model illus-
trated in Fig. 10. As shown in Fig. 10C, our present study
suggests that displacement of N terminus of caldesmon from
myosin by IK29C may affect the “proper positioning” of the C
terminus of caldesmon required for its inhibitory action on
actin-activated myosin ATPase. Caldesmon displaced from this
proper position would lead to disinhibition of actomyosin inter-
action and the resultant IK29C-induced contraction (Fig. 10C).
This model is also consistent with a prevention of the PE-
induced contraction in the presence of the peptide if they act
through the same mechanism (Fig. 10D). We also found that
post-treatment of the portal vein cells with IK29C had no effect
on contraction induced by maximally effective concentration of
PE. Thus, the peptide can prevent but not reverse the PE-
induced contraction. It might be expected, if tethering of actin
and myosin by caldesmon were involved in force maintenance,
that the peptides would decrease force maintenance by break-
ing the tethers; however, if the C-terminal end of caldesmon is
already disinhibited, the peptide would have no effect (Fig.
10D).
Although the results of the present study are consistent with
the above model, we cannot rule out alternative interpreta-
tions, such as the possibility that the interaction of the N-
terminal domain of CaD with myosin is inhibiting by constrain-
ing the position of the myosin head and that the CaD peptides
relieve this constraint.
In conclusion, peptides from the myosin binding N-terminal
region of caldesmon caused contraction of vascular smooth
muscle cells and selectively prevented contraction by PE. These
results are consistent with, but do not prove, the hypothesis
that tethering of N-terminal of caldesmon may play a role in
regulating vascular tone by positioning the C terminus of
caldesmon so that it is capable of inhibiting actin-activated
myosin ATPase.
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